Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

About this update from Zai Lab Ltd.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/4a281ea1c534e76a1298f3e0e28905e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q74oRfkD1CK084Qxc9ocwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4a281ea1c534e76a1298f3e0e28905e9","width":480,"height":224}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial","length":280,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology","length":153,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":616,"olType":false},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland, May 31, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology.","length":452,"tagName":"p"},{"type":"text","content":""The data presented today from the PANOVA-3 trial of Tumor Treating Fields show a clinically meaningful and statistically significant improvement in overall survival for people with locally advanced pancreatic cancer," said Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial. "Importantly, we also saw an extension in the duration of time before pain progressed. Pai...

More updates from Zai Lab Ltd.